Replies to post #143882 on Biotech Values

[pollyvonwog]

TEVA thinks they could nab 30% (from an analyst report I get):

"Our conversations with Teva management as well as physicians indicate that around 30% of the Copaxone franchise could be converted to the less frequent dosing regimen should it ultimately receive FDA approval."

It goes on to say that they expect TEVA to file for approval this year, FWIW.

[genisi]

If approved, and I think it will, the thrice-weekly Copaxone will be strongly promoted by Teva but I think they might have too little time to convert before it goes generic.

[zipjet]

IMO—I doubt that many MS patients will even know about the new Copaxone option unless they are made aware of it by their neuro.

I think the neuro's will tell their patients unless they think compliance would suffer - which I think it would. It is easier to get in the habit of doing something every day.

IF there is no change in the NCE, why couldn't the generic provider get approval for the new thrice weekly dose?

ij